dont tell anyone im buying., page-10

boston scientific Appointment of New Chief Executive Officer
The Board of HeartWare is pleased to announce the appointment of Mr Douglas Godshall as HeartWare’s new
Chief Executive Officer, effective from 18 September 2006. Mr Godshall takes over from Mr Stuart
McConchie who has resigned from the position.
Prior to accepting the position at HeartWare, Mr Godshall served on the Operating Committee at Boston
Scientific Corporation (Boston Scientific), one of the world’s largest medical device companies.
Since January 2005 Mr Godshall has been President, Vascular Surgery at Boston Scientific, with overall
responsibility for a business division employing some 600 personnel and generating revenues of approximately
US$100M. Mr Godshall previously spent five years as Vice President, Business Development at Boston
Scientific, where he was instrumental in developing the acquisition strategies for the cardiology,
electrophysiology, neuroradiology and vascular surgery divisions. During this period Mr Godshall led the
negotiation and structuring of over 70 transactions and represented Boston Scientific on the Boards of 11
companies. Prior to assuming the Business Development position, he was Director of Marketing for Boston
Scientific’s Urology Division where he helped build global sales to over US$150M. Mr. Godshall joined
Boston Scientific in 1990.
HeartWare Chairman, Mr Rob Thomas, said:
“On behalf of the Board I am delighted to welcome Doug to HeartWare. Having spent over fifteen years in a
range of progressively more senior positions at Boston Scientific, Doug brings to HeartWare a depth of
expertise across all facets of the medical device business. He has established and led executive teams through
the clinical development, market launch and subsequent commercial rollout of a range of medical devices in
the United States and around the world. He has exceptional credentials as a strategic leader and a track
record of identifying and successfully executing a number of substantial business partnerships and corporate
transactions.
Doug also brings to HeartWare a breadth of financial, strategic and operational relationships in the United
States, the world’s largest medical device market. These will be of critical importance to the Company over the
coming years.
The Board would like to extend its sincere thanks to outgoing Chief Executive Mr Stuart McConchie who has
made a significant contribution during his time with the Company. During this period, HeartWare listed on the
Australian Stock Exchange and successfully completed two substantial capital raisings. More importantly,
Stuart oversaw the Company’s transition from a pre-clinical technology developer into a clinically focused
medical device manufacturer. With a strong executive team now in place and compelling clinical validation of
its technology, HeartWare is well-placed to move towards its commercial phase.”
Incoming Chief Executive Officer, Mr Douglas Godshall commented:
“Congestive heart failure (CHF) is among the most prevalent diseases in the world. CHF patients, particularly
those with advanced disease, have few treatment options. The ventricular assist devices available today have
already created a substantial market and clearly point to a tremendous growth opportunity when smaller, more
reliable pumps become available. HeartWare has the product portfolio, intellectual property, clinical
credibility and internal resources necessary to establish a major presence in this market.